The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.
“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.
The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.
“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.
“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”
Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.
“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”
Executive Director Sarah Helm reflects on this year's global drug conference
As harm reduction advocates in Aotearoa push for better naloxone access, we look for lessons across the ditch.
We've launched a new tool to help you find the latest drug data and changed how we report throughout the year.